Otiprio FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
FDA Approved: Yes (First approved December 10, 2015)
Brand name: Otiprio
Generic name: ciprofloxacin
Dosage form: Otic Suspension
Previous Name: AuriPro
Company: Otonomy, Inc.
Treatment for: Tympanostomy Tube Placement Surgery; Acute Otitis Externa
Otiprio (ciprofloxacin otic suspension) is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery, and for the treatment of acute otitis externa due to Pseudomonas aeruginosa and Staphylococcus aureus.
Development timeline for Otiprio
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
